# PTPRN

## Overview
PTPRN, or protein tyrosine phosphatase receptor type N, is a gene that encodes a receptor-type protein tyrosine phosphatase, commonly referred to as IA-2 or ICA512. This protein is categorized as a type I transmembrane protein and is predominantly expressed in neuroendocrine cells, including insulin-secreting pancreatic β-cells and various neurons. PTPRN plays a critical role in neuroendocrine processes, particularly in the regulation of insulin secretion and glucose homeostasis, by participating in vesicle trafficking and exocytosis. The protein's involvement in cellular signaling pathways underscores its importance in maintaining endocrine function and metabolic regulation. Additionally, PTPRN is recognized as an autoantigen in type 1 diabetes, with its autoantibodies serving as predictive markers for the disease. The gene's expression and interactions have significant implications in various cancers, including lung adenocarcinoma and colorectal cancer, where it influences tumor progression and immune responses (Li2022PTPRN; Admin2022Seroreactivity; Song2021Overexpression).

## Structure
PTPRN, also known as IA-2 or ICA512, is a receptor-type protein tyrosine phosphatase with a specific domain architecture. It includes an extracellular N-terminal RESP18 domain, a membrane-proximal Receptor IA-2 domain with a ferredoxin-like fold, a single transmembrane helix, and a PTP domain (Bhattacharyya2019GenomeWide). The protein is primarily expressed in neuroendocrine cells, such as insulin-secreting pancreatic β-cells, where it plays roles in granule cargo storage, exocytosis, and cell proliferation (El2024Analysis).

PTPRN undergoes proteolytic processing by furin-like convertases, which cleaves off a large N-terminal fragment, leaving a transmembrane protein of approximately 60 kDa (El2024Analysis). The mature extracellular domain is related to the SEA domain of mucins and is initially oriented towards the lumen of the granule, later facing the extracellular space following granule secretion (El2024Analysis).

PTPRN is also known to be an autoantigen in type 1 diabetes, with autoantibody detection used as a predictive marker for the disease (El2024Analysis). The protein's intracellular domain can translocate to the nucleus upon exocytosis, where it interacts with E3-SUMO ligase PIASy to upregulate insulin expression (Bhattacharyya2019GenomeWide).

## Function
PTPRN, also known as islet cell autoantigen 512 (ICA512/IA-2), is a type I transmembrane protein primarily expressed in neuroendocrine cells and neurons, including those in the pancreas, pituitary, adrenal medulla, amygdala, and hypothalamus (Li2022PTPRN; Wang2021Expression). In healthy human cells, PTPRN is involved in neuroendocrine processes such as the biogenesis, transport, and regulation of exocytosis. It plays a crucial role in the secretion pathways of various neuroendocrine cells, particularly in the regulation of insulin secretion in pancreatic beta cells (Li2022PTPRN; Song2021Overexpression).

PTPRN's function in insulin secretory granules is significant for maintaining glucose homeostasis, as it is involved in vesicle trafficking and exocytosis (Song2021Overexpression). The protein's activity is linked to the regulation of cell signaling pathways, which are essential for proper endocrine function and metabolic regulation. PTPRN's expression and function in healthy cells are integral to its role in neuroendocrine processes, highlighting its importance in both cellular and organismal physiology (Li2022PTPRN).

## Clinical Significance
The PTPRN gene has significant clinical implications in various cancers and diseases. In lung adenocarcinoma (LUAD), PTPRN is overexpressed and associated with increased metastasis and reduced natural killer (NK) cell cytotoxicity, contributing to poor overall survival in patients. This overexpression promotes cell migration and influences epithelial-mesenchymal transition (EMT) markers through the MEK/ERK and PI3K/AKT signaling pathways, highlighting its potential as a therapeutic target for modulating antitumor immune responses in LUAD treatment (Song2021Overexpression).

In colorectal cancer (CRC), PTPRN expression is higher in cancerous tissues compared to normal tissues and is linked to worse overall and disease-free survival. PTPRN depletion in CRC cells reduces their invasiveness and metastatic potential, suggesting its role in EMT and insulin receptor signaling pathways. PTPRN autoantibody levels can discriminate between CRC patients and non-diabetic individuals, particularly in those with Type 2 Diabetes (T2D), indicating its potential as a diagnostic marker (Admin2022Seroreactivity).

In low-grade glioma (LGG), decreased PTPRN expression is associated with poorer overall survival, and its expression correlates with immune cell infiltration in tumors. This suggests PTPRN's involvement in modulating the tumor microenvironment and its potential as a prognostic biomarker (Li2022PTPRN).

## Interactions
PTPRN, also known as IA-2, is involved in several protein interactions that influence its function in cellular processes. It interacts with Heat Shock Protein 90 Alpha Family Class A Member 1 (HSP90AA1), which activates the PI3K/AKT signaling pathway, promoting glioma cell proliferation and migration (Wang2021Expression). This interaction is significant in the context of glioma, where PTPRN's overexpression is linked to poor prognosis (Wang2021Expression).

PTPRN is also known to interact with the E3-SUMO ligase protein inhibitor of activated signal transducer and activator of transcription-y (PIASy) in the nucleus. This interaction is crucial for upregulating insulin expression, highlighting PTPRN's role in insulin secretion and its relevance as an autoantigen in Type I diabetes (Bhattacharyya2019GenomeWide).

In the context of neuroendocrine cells, PTPRN forms heterodimers with other receptor-type protein tyrosine phosphatases, such as RPTPα and RPTPε, potentially modulating their activity, although this function is not fully established at the physiological level (TORII2009Expression). These interactions underscore PTPRN's multifaceted role in both oncogenic and endocrine pathways.


## References


[1. (El2024Analysis) Lina El Badaoui and Alastair J. Barr. Analysis of receptor-type protein tyrosine phosphatase extracellular regions with insights from alphafold. International Journal of Molecular Sciences, 25(2):820, January 2024. URL: http://dx.doi.org/10.3390/ijms25020820, doi:10.3390/ijms25020820. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms25020820)

[2. (Li2022PTPRN) Peng Li, Fanfan Chen, Chen Yao, Kezhou Zhu, Bei Zhang, and Zelong Zheng. Ptprn serves as a prognostic biomarker and correlated with immune infiltrates in low grade glioma. Brain Sciences, 12(6):763, June 2022. URL: http://dx.doi.org/10.3390/brainsci12060763, doi:10.3390/brainsci12060763. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/brainsci12060763)

[3. (Song2021Overexpression) Xinyue Song, Xue Jiao, Han Yan, Lifeng Yu, Longyang Jiang, Ming Zhang, Lianze Chen, Mingyi Ju, Lin Wang, Qian Wei, Lin Zhao, and Minjie Wei. Overexpression of ptprn promotes metastasis of lung adenocarcinoma and suppresses nk cell cytotoxicity. Frontiers in Cell and Developmental Biology, June 2021. URL: http://dx.doi.org/10.3389/fcell.2021.622018, doi:10.3389/fcell.2021.622018. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2021.622018)

[4. (Wang2021Expression) Dong Wang, Fan Tang, Xi Liu, Yueshan Fan, Yu Zheng, Hao Zhuang, Budong Chen, Jie Zhuo, and Bo Wang. Expression and tumor-promoting effect of tyrosine phosphatase receptor type n (ptprn) in human glioma. Frontiers in Oncology, September 2021. URL: http://dx.doi.org/10.3389/fonc.2021.676287, doi:10.3389/fonc.2021.676287. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2021.676287)

5. (Admin2022Seroreactivity) Seroreactivity against tyrosine phosphatase PTPRN links Type 2 Diabetes and Colorectal Cancer and identifies a Potential diagnostic and Therapeutic Target. This article has 0 citations.

[6. (TORII2009Expression) Seiji TORII. Expression and function of ia-2 family proteins, unique neuroendocrine-specific protein-tyrosine phosphatases. Endocrine Journal, 56(5):639–648, 2009. URL: http://dx.doi.org/10.1507/endocrj.k09e-157, doi:10.1507/endocrj.k09e-157. This article has 41 citations and is from a peer-reviewed journal.](https://doi.org/10.1507/endocrj.k09e-157)

[7. (Bhattacharyya2019GenomeWide) Teerna Bhattacharyya and Ramanathan Sowdhamini. Genome-wide search for tyrosine phosphatases in the human genome through computational approaches leads to the discovery of few new domain architectures. Evolutionary Bioinformatics, January 2019. URL: http://dx.doi.org/10.1177/1176934319840289, doi:10.1177/1176934319840289. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1177/1176934319840289)